Structure-activity relationship of 5,6-dihydro-tetrazolo[1,5-c]quinazolines targeting Candida glabrata

Abstract

Candida species cause both disseminated and superficial fungal infections in humans. Although azole antifungals have historically proven effective in treating such infections, recent epidemiological studies highlight a crucial concern in the clinical context. Some Candida species exhibit inherent resistance to azoles and echinocandins, and the emergence of high-level resistance poses a significant problem. Consequently, derivatives of 5,6-dihydrotetrazolo[1,5-c]quinazolines have shown potent inhibitory properties against C. glabrata at concentrations range of 0.4 – 55.0 μM, leading to the identification of a structure-activity relationship.